Atossa Genetics (ATOS) Posts Narrower Q2 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Atossa Genetics (ATOS) Posts Narrower Q2 Loss

Atossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update

August 12, 2016 8:00 AM EDT

SEATTLE, WA -- (Marketwired) -- 08/12/16 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced Second Quarter ended June 30, 2016 financial results and provided an update on recent company developments.

Dr. Steve Quay, President and CEO, commented, "We are encouraged by our continued progress on both our recently announced new drug development program with oral endoxifen and our ongoing Phase 2 clinical trial of intraductal fulvestrant administration in women with ductal carcinoma in situ (DCIS) or invasive breast cancer." Dr. Quay continued, "With our recently announced settlement with Besins Healthcare, we will have an additional $1.76... More